October 2010 Briefing - Ophthalmology
Here are what the editors at HealthDay consider to be the most important developments in Ophthalmology for October 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Primary Care Trails Other Specialties in Hourly Wages
TUESDAY, Oct. 26 (HealthDay News) -- Primary care physicians have substantially lower hourly wages than other specialists, and although most physicians find Medicare reimbursement inequitable, they show little consensus on how to reform it, according to two studies published in the Oct. 25 issue of the Archives of Internal Medicine.
Eye Damage Seen in Anorexia Nervosa
FRIDAY, Oct. 22 (HealthDay News) -- Anorexia nervosa (AN) may cause serious eye damage, even without noticeable vision loss, according to research published online Oct. 19 in the British Journal of Ophthalmology.
FDA Issues Warnings About Unapproved "Chelation" Drugs
FRIDAY, Oct. 15 (HealthDay News) -- The U.S. Food and Drug Administration has notified health care professionals and consumers that no evidence has proved that nonprescription "chelation" products actually rid the body of toxic metals and can treat a variety of serious conditions and diseases.
Use of 'Poppers' Linked to Vision Loss in Several Patients
WEDNESDAY, Oct. 13 (HealthDay News) -- Alkyl nitrite "poppers" -- which have long been used as a recreational drug -- may be associated with phosphenes and prolonged vision loss, according to a letter published in the Oct. 14 issue of The New England Journal of Medicine.
Macular Degeneration Treatments Assessed
TUESDAY, Oct. 12 (HealthDay News) -- Among patients with age-related macular degeneration, the use of bevacizumab and ranibizumab is not associated with higher risk of adverse outcomes including death, myocardial infarction, bleeding, and stroke, according to research published in the October Archives of Ophthalmology.